Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bictegravir.

Vincenzo Spagnuolo1,2, Antonella Castagna1,2, Adriano Lazzarin2

  • 1Vita-Salute San Raffaele University.

Current Opinion in HIV and AIDS
|May 11, 2018
PubMed
Summary

Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) is a new HIV-1 treatment option. Clinical trials show B/F/TAF is effective and well-tolerated in treatment-naïve and virally suppressed individuals.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Three settings, one goal: Performance of different HIV testing strategies at a tertiary centre in Milan.

HIV medicine·2026
Same author

Changing Clinical and Laboratory Characteristics of Progressive Multifocal Leukoencephalopathy: A Retrospective National Cohort Study.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2025
Same author

Switch to bictegravir/emtricitabine/tenofovir alafenamide from dolutegravir-based therapy.

AIDS (London, England)·2024
Same author

No need to modify treatment within the first month after rapid start of a tailored antiretroviral therapy: the TWODAY Study.

The new microbiologica·2023
Same author

Bictegravir/emtricitabine/tenofovir alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trials.

EClinicalMedicine·2023
Same author

Evaluation of HIV-DNA and residual viremia levels through week 96 in HIV-infected individuals who continue a two-drug or switch to a three-drug integrase strand transfer inhibitor-based regimen.

International journal of antimicrobial agents·2023

Area of Science:

  • Infectious Diseases
  • Virology
  • Pharmacology

Background:

  • HIV-1 infection remains a significant global health challenge.
  • Antiretroviral therapy is crucial for managing HIV-1.
  • Integrase strand transfer inhibitors (INSTIs) are a key class of antiretrovirals.

Purpose of the Study:

  • To review the efficacy and safety of bictegravir (BIC) coformulated with emtricitabine and tenofovir alafenamide (B/F/TAF).
  • To evaluate B/F/TAF for treatment of HIV-1 in antiretroviral-naïve and virally suppressed subjects.

Main Methods:

  • Review of preclinical data on BIC's genetic barrier and in vitro activity.
  • Analysis of Phase 3 clinical trials (GS-US-380-1489 and GS-US-380-1490).
  • Evaluation of safety, tolerability, and resistance data.

Related Experiment Videos

Main Results:

  • BIC demonstrates a high genetic barrier to resistance, comparable to dolutegravir (DTG).
  • B/F/TAF is non-inferior to DTG-containing regimens in treatment-naïve subjects.
  • B/F/TAF shows excellent tolerability with no observed treatment-emergent resistance.

Conclusions:

  • Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) represents a significant advancement in HIV-1 management.
  • B/F/TAF offers a new, effective, and well-tolerated option for both treatment-naïve and suppressed patients.
  • Preliminary data suggest B/F/TAF is a viable switch option for patients with undetectable viral load.